Fourth and last, in case reports or small case series, the effect of B cell depleting therapy with rituximab has been described in patients with anti-IFNγ auto-antibodies whose infections were refractory to antibiotic therapy, all with good clinical effect and little side effects and resulting in sustained remission [37,38,39,40,41,42,43]. The gene discussed is IFNG; the disease is infection.